This article details the methods that are used to expand human fetal brain neural stem cells in culture, as well as how to differentiate them into various neuronal subtypes and astrocytes, with an emphasis on the use of neural stem cells to study Zika virus infection.
Human fetal brain neural stem cells are a unique non-genetically modified model system to study the impact of various stimuli on human developmental neurobiology. Rather than use an animal model or genetically modified induced pluripotent cells, human neural stem cells provide an effective in vitro system to examine the effects of treatments, screen drugs, or examine individual differences. Here, we provide the detailed protocols for methods used to expand human fetal brain neural stem cells in culture with serum-free media, to differentiate them into various neuronal subtypes and astrocytes via different priming procedures, and to freeze and recover these cells. Furthermore, we describe a procedure of using human fetal brain neural stem cells to study Zika virus infection.
Zika virus (ZIKV) is a flavivirus transmitted either sexually, or by the mosquito vectors Aedes aegypti and Aedes albopictus mosquitoes. ZIKV was recently identified as a severe public health threat due to its ease of transmission and affiliated neurological symptoms1. One of the most concerning neurological effects is the development of microcephaly in fetuses born to pregnant infected mothers2,3. Microcephaly is a neurodevelopmental disorder where the head is smaller than the typical size during fetal development and at birth, with the circumference less than 2 standard deviations below the mean4. The smaller head circumference is commonly accompanied by a variety of comorbidities such as developmental delays, seizures, vision and hearing loss, and feeding difficulty.
Recent studies have used animal models or induced pluripotent stem cells to study the effect of ZIKV infection on neurodevelopment5,6,7,8. While these studies have contributed to our knowledge of ZIKV, the use of different species or genetically modified cells may be time consuming and/or add additional variables that may confound the effect of ZIKV on developing neural cells5,6,7,8. However, the difficulty with hNSC culture, particularly the non-adherent neurosphere culture described in this protocol, is that the culture is very sensitive to the methods used to conduct the culture9. Any change in medium components, or even the physical handling of the culture vessel, is enough to elicit a reaction from the cells9. To address these issues, we developed an in vitro human fetal brain-derived neural stem cell (hNSCs) culture to mechanistically interrogate the effect of ZIKV on fetal neural stem cells. Using our method, hNSCs were maintained for over 80 passages without apparent phenotypic changes10. Furthermore, chromosomal alterations such as trisomy were either none or minimal11. This hNSC culture grows as a non-adherent neurosphere culture. One advantage of neurospheres is that the spheres create a unique environmental niche in culture that is more reflective of in vivo niches compared to two-dimensional cultures9. Another advantage of this protocol is that multiple cell types can be derived from the hNSC culture, enabling an investigator to observe the impact of a given variable on hNSC survival and differentiation. This protocol is applicable to individuals looking to answer mechanistic questions regarding central nervous system development or dysfunction. The following protocol describes how to expand a hNSC culture to infect with ZIKV, and subsequently differentiate the hNSCs to observe the impact of infection on the differentiation process. It also includes methods to store hNSCs for long-term usage, and to differentiate hNSCs into various types of neurons that allow further investigation of ZIKV-induced deficits contributing to brain malformation11. We believe this protocol is also of interest to investigators seeking to understand the impact of any environmental stimulus such as infection or toxins on neural stem cell survival and differentiation.
Human neural stem cells were originally derived from discarded human fetal cortexes in the first trimester12. All protocol procedures adhere to the University of Texas Medical Branch ethics guidelines concerning the use of human tissue samples, and the cell lines were approved by the Institutional Biosafety Committee.
1. Stock medium preparation and stem cell recovery
2. hNSC Medium Change
NOTE: Change medium every 3-4 days .
3. hNSC Passage
NOTE: hNSCs should be passage every 9-11 days if cells grow normally, as population doubling time is approximately 3 days13.
4. hNSC Freezing and Storage
5. Plating adherent hNSC for validation
6. Priming to obtain GABA and glutamate neurons
7. Priming to obtain motor neurons
8. Zika Virus Infection
NOTE: ZIKV is highly sensitive to temperature, so it is imperative that ZIKV stock are stored at -80 °C and freeze/thawing cycles are avoided. Keep working aliquots on ice.
9. Staining procedure
Cultured hNSCs in their proliferative stage will grow as non-adherent neurospheres (Figure 1). Immediately following hNSC passage, there will be many individual cells, which will aggregate and begin to form spheres in the next few days (Figure 1A and 1B). Healthy spheres should be approximately 1-2 mm in diameter 9-10 days following a passage (Figure 1C). Spheres that grow larger than 2 mm will develop a dark center and the growth factors in the medium will not be able to reach the cells in the center of the sphere, resulting in unwanted differentiation. Healthy spheres will appear translucent and display pseudo-cilia around the edges of the sphere (Figure 1C).
Plating neurospheres on an adherent surface for staining purposes will result in the growth of adherent spheres (Figure 2A). These spheres will touch the surface of the culture vessel and have some projections stretching out on the surface of the vessel, while maintaining a central sphere (Figure 2A). Priming and differentiating the cells require the cells to adhere to a cover slip at the bottom of a cell culture plate, such as a 24-well plate. Following the appropriate priming steps and addition of differentiation medium, the cells will spread out across the surface of the culture vessel and grow as interconnected monolayer of cells (Figure 2B).
To either confirm the validity of the hNSC culture or phenotype of differentiated cells, fluorescent immunohistochemistry can be used. Nestin is an intermediate filament commonly expressed in NSCs and can be used to verify hNSC culture (Figure 3A). To verify the presence of neurons following differentiation, class III β-tubulin can generally be used to label neurons (Figure 3B). Although the priming step is used to achieve a higher percentage of neurons following differentiation, there will still be astrocytes in the culture. Glial fibrillary acidic protein (GFAP) can be used to label astrocytes in order to quantify which percentage of differentiated cells became astrocytes or neurons.
We found that the K048 line of NSCs was infected by both African and Asian strains of ZIKV detected by immunofluorescent staining with a specific ZIKV antibody. The representative images are shown in Figure 4. Mock infection did not elicit a change in hNSC morphology or survival (Figure 4A, 4C). ZIKV tends to stay in the peripheral region of an infected cell one day post a 1-hour infection, but fills the whole cell at 3 to 7 days (Figure 4B, 4D, 4E). Noticeably, with the same MOI (0.1), an estimated 5% infection rate in K048 cells is substantially lower than those recently reported ZIKV infection rate (up to 80%) in human skin-induced NSCs7. This study, reporting 80% infectivity, used the prototype African strain of ZIKV (MR766) that may have adapted a neurotropic phenotype during over 140 passages in mouse brain cells.
Figure 1: Bright field images of hNSC culture. (A-C) Representative bright field images taken at 10X magnification of hNSC culture 1, 4 and 9 days after passaging, respectively. Scale bars: 60 µm. Please click here to view a larger version of this figure.
Figure 2: Bright field images of adherent cultures. (A) Representative bright field images taken at 10X magnification of adherent hNSC culture, 7 days after plating. (B) Representative bright field images taken at 10X magnification of adherent differentiated cells following ELL priming and 9 days of differentiation. Scale bars: 60 µm. Please click here to view a larger version of this figure.
Figure 3: Fluorescent images of hNSCs and differentiated cultures. (A) Representative fluorescent images taken at 20X magnification of adherent hNSCs stained with nuclear marker, DAPI (blue), and stem cell marker Nestin (red). Scale bar: 60 µm (B) Representative fluorescent images taken at 60X magnification of differentiated cells stained with neural marker βIII-tubulin (green), astrocyte maker GFAP (red), and nuclear marker DAPI (blue). Scale bars: 10 µm. Please click here to view a larger version of this figure.
Figure 4: ZIKV infection in human fetal brain-derived NSCs. Human NSCs were either Mock treated (A and C), inoculated for 1 hour with an African lineage strain of ZIKV at MOI of 0.1 (B and D), or with an Asian strain of ZIKV recently isolated from mosquitoes in Mexico in 2016 (E). Immunofluorescent staining detects labeling of ZIKV antibodies in NSCs at one to seven days post inoculation (1 dpi in B, 7dpi in D, and 3 dpi in E). Scale bars 10 µm in A-D, and 5 µm in E. Please click here to view a larger version of this figure.
DFHGPS media for one T75 | 10 mL |
TPPS* | 173 µL |
200 mM L-Glutamin | 50 µL |
10 mg/mL Insulin** | 25 µL |
20 µg/mL Epidermal growth factor | 10 µL |
20 µg/mL Basic fibroblast growth factor | 10 µL |
10 µg/mL Leukemia inhibitor factor | 10 µL |
5 mg/mL Heparin | 10 µL |
* Mixture containing 100 µg/mL Transferrin, 100 µM putresine, 20 nM progesterone, and 30 nM sodium selenite. The mixture is made from concentrated stocks, and aliquots are stored at -80 °C and preferablly used within 6 weeks preparation. The concentrated stocks are 10 mg/mL transferrin, 30 mM putrescine, 10 µM progesterone and 15 µM sodium selenite stored at -80 ˚C. | |
** Insulin is dissolved in 0.01 N hydroen chloride, filtered through 0.2 µM low protein binding filter, and stored at 4 ˚C for up to 6 weeks. |
Table 1: Growth factors for New Proliferation Medium.
dPBS* | 1 mLa | 3 mLb |
10% glucose | 60 µL | 180 µL |
2.5% Trypsin | 10 µL | 30 µL |
Dnase** | 5 µL | 15 µL |
* Dulbecco's phosphate-buffered saline | ||
** Deoxyribonuclease | ||
a for 10 million cells | ||
b for 30 million cells |
Table 2: Preparation of trypsin.
Conditioned media | 1 mLa | 3 mLb |
Trypsin Inhibitor | 10 µL | 30 µL |
a for 10 million cells | ||
b for 30 million cells |
Table 3: Preparation of trypsin inhibitor.
DFHGPS* | 0.7 mLa | 2.1 mLb |
FBS** 20% | 0.2 mL | 0.6 mL |
DMSO*** 10% | 0.1 mL | 0.3 mL |
* DMEM, F12, HEPES, glucose, penicillin-streptomycin | ||
** Fetal bovine serum | ||
*** Dimethyl sulfoxide | ||
a for 5 million cells in one vial | ||
b for three vials, 5 million cells/vial |
Table 4: Preparation of freezing medium.
DFGHPS* for one well in a 24-well plate | 1 mL |
TPPS** | 17.3 µL |
200 mM L-glutamine | 5 µL |
10 mg/mL Insulin | 2.5 µL |
20 µg/mL Epidermal growth factor | 1 µL |
10 µg/mL Leukemia inhibitory factor | 1 µL |
1 mg/mL Laminin | 1 µL |
* Containing DMEM, F12, HEPES, glucose, penicillin-streptomycin | |
** Containing 100 µg/mL Transferrin, 100 µM putresine, | |
20 nM progesterone, and 30 nM sodium selenite |
Table 5: Preparation of ELL priming medium.
DFGHPS* for one well in a 24-well plate | 1 mL |
TPPS** | 17.3 µL |
200 mM L-glutamine | 5 µL |
10 mg/mL Insulin | 2.5 µL |
20 µg/mL basic fibroblast growth factor | 0.5 µL |
5 mg/mL Heparin | 0.5 µL |
1 mg/mL Laminin | 1 µL |
* Containing DMEM, F12, HEPES, glucose, penicillin-streptomycin | |
** Containing 100 µg/mL Transferrin, 100 µM putresine, | |
20 nM progesterone, and 30 nM sodium selenite |
Table 6: Preparation of FHL priming medium.
The ability to culture and manipulate hNSCs provides a critical tool that can be used for a variety of purposes from modeling human disease to high throughput drug screening10,11,12,14,15,16,17. Many questions remained to be addressed such as how human fetal brain NSCs or their progeny are susceptible to ZIKV infection, whether different strains of ZIKV infect NSCs with equal efficiency, and how infection during neural development results in microcephaly. We have used this hNSC culture to investigate Zika virus associated neuropathology11,14. By using three strains of cells isolated from three individual donors, we are also able to compare individual differences to susceptibility to the neurological deficits observed following ZIKV infection11. One of the limitations of this technique is the accessibility to hNSC samples and the conditioned medium essential for proper culture. To circumvent this barrier, please contact the corresponding author to arrange a material transfer as the cells used in this protocol are not commercially available.
In vitro studies using hNSCs not only provide unique insight into basic stem cell behavior, they also provide an excellent platform to conduct pre-clinical research. However, the technical challenges of culturing hNSCs can serve as an obstacle in using them as effective and reproducible models. In this protocol, we have outlined key steps and methodologies that can be used to reduce variability in culturing methods and yield a healthy and stable hNSC stem cell culture. A drawback of using hNSC neurosphere culture is that the cells are extremely sensitive to any and all stimuli. Even with the detailed protocol above, it is critical to pay close attention to how much the flasks or dishes of hNSCs are handled, as the subtlest variations on the protocol can result in changes in the neurosphere behavior.
The most crucial part of this methods paper is the cocktail of growth factors and preparation of the different media. If the doubling time of the hNSC culture is very low, or many cells adherie to the culture vessel (when they should be non-adherent), the first step is to ensure that the growth factors being used are the appropriate concentration and not expired. All growth factors in this protocol have a very short shelf life once thawed (5-6 days). Additionally, we have used growth factors from multiple companies and noticed differences in the quality and concentration needed to maintain the culture. Therefore, we highly recommend using the exact growth factors detailed in the Materials Table. The passaging step (steps 3.1-3.22) is also a common source of error. If there are many dead cells following the dissociation process, reduce the number of times of pipetting up and down to dissociate the cells, as too much physical dissociation can result in cell death. Alternatively, if there are many clusters of cells following the dissociation step, increase the vigor or number of times of pipetting up and down, as these clusters will quickly become large spheres that will not remain viable in culture. If the culture is properly maintained, infection with ZIKV is relatively straightforward.
While ZIKV infection is the treatment detailed in this protocol, it is possible to use this hNSC culture system for a wide array of studies. This model system can be used to screen drugs, examine individual susceptibility, and investigate underlying mechanisms of a variety of diseases and developmental disorders14. This system is also ideal for genomic studies since the cultured cells have not been genetically manipulated and show little to no chromosomal abnormalities, even up to 80 passages10,11. We believe this culture system is ideal for modeling in vitro how environmental stimuli such as infection, drugs, alcohol, toxins, etc. can influence development of the nervous system.
The authors have nothing to disclose.
This work was supported by funds from the John S. Dunn Foundation and the Institute for Human Infections and Immunity of the University of Texas Medical Branch (P.W.).
DMEM | Gibco | 11965-092 | |
F12 | Gibco | 11765-054 | |
Glucose (10%) | Sigma | G8644 | |
HEPES (1M) | Corning/cellgro | 25-060-c1 | |
Pen Strep (100x) | Gibco | 15140-122 | |
Insulin | Sigma | I4011 | |
L-Glutamine | Gibco | 25030-081 | |
Transferrin | Sigma | T2036 | |
Progesterone | Sigma | P8783 | |
Putrescine | Sigma | P5780 | |
Sodium selenite | Sigma | S5261 | |
Heparin Sigma | Sigma | H3149 | |
basic fibroblast growth factor | R&D system | 233-FB | |
epidermal growth factor | R&D system | 236-EG | |
leukemia inhibitory factor | R&D system | 7734-LF | |
Laminin | Invitrogen | 23017-015 | |
2.5% trypsin | Gibco | 15090-046 | |
Trypsin inhibitor | Sigma | T6522 | |
Poly-D-Lysine hydrobromide(PDL) | Sigma | P6407-5MG | |
B-27 supplement | Gibco/Invitrogen | 17504-044 | |
Fetal bovine serum | Gibco | 16000-044 | |
Dimethyl sulfoxide | Sigma | D2650-100ml | |
Dulbecco's phosphate-buffered saline | Corning/cellgro | 21-031-CV | |
Bovine serum albumin | Sigma | A4378-25G | |
Normal goat serum | Jackson ImmunoResearch Lab | 005-000-121 | |
Triton X-100 | FisherBiotech | BP151-500 | |
Nestin antibody | BD Transduction Laboratories | 611659 | 1:200 dilution |
Class III beta-tubulin antibody (TuJ1) | Covnce | MMS-435p | 1:2000 dulution |
GFAP antibody | Millipore | AB5804 | 1:1000 dilution |
DAPI | Molecular Probes | D1306 | 1:2000 dilution |
ZIKV antibody | World Reference Collection for Emerging Viruses and Arboviruses at the University of Texas Medical Branch | 1:2000 dilution | |
Fluoromount G | SouthernBiotech | 0100-01 | |
CO2 incubator | Thermo Forma | Model# 3110 | |
Centrifuge | Thermo fisher Scientific | 75004221 | |
Biological safety cabinet | Forma scientific Claas II A/B3 | Model# 1284 | |
Freezer (-80 °C) | Forma scientific,Inc | model# 8516 | |
Microscope(phase contrast image) | Hp 2230 workstation | Product#NOE25us#ABA | |
Microscope (epifluorescent image) | Nikon Eclipse 80i | ||
Confocal Microscope | Nikon TE2000-E microscope with C1si confocal system |